

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT

MARKETING APPLICATION FOR ASANDEUTERTINIB MESYLATE TABLETS (TY-9591) HAS OBTAINED CONDITIONAL APPROVAL GRANTED BY NMPA

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company’s self-developed Asandeutertinib Mesylate Tablets (TY-9591), a next-generation EGFR-TKI, has obtained conditional approval for marketing granted by the National Medical Products Administration of China (the “**NMPA**”), with the indication being: first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), central nervous system (CNS) metastases harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutation.

About Asandeutertinib Mesylate Tablets

Asandeutertinib Mesylate Tablets, self-developed by the Company, is an irreversible, oral, new-generation, highly selective EGFR-TKI and a deuterated innovative agent differentiated from osimertinib. Through unique structural optimization, Asandeutertinib Mesylate Tablets effectively reduce the formation of toxic metabolites and exhibits superior pharmacodynamic profiles. It has demonstrated prominent clinical efficacy and safety advantages in patients with brain metastasis from lung cancer with EGFR 19del and L858R mutation. At present, the Company has launched multiple clinical studies in monotherapy and in combination with other agents, comprehensively covering various sub-indications of advanced non-small cell lung cancer.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize Asandeutertinib Mesylate Tablets successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 27, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.